Luis E. Raez, Medical Director of Memorial Cancer Institute and Co-Director of MCI/FAU Florida Cancer Center of Excellence, shared a post by Stephen V Liu, Associate Professor of Medicine at Georgetown University, adding:

“This is important data because its real world and give as a reason to always use the best therapy first, in the EGFR case is combination therapy either MARIPOSA or FLAURA2, no more single therapy unless there is a reason.”

Quoting Stephen V Liu‘s post:

“Real world outcomes for EGFR NSCLC with 1L osimertinib JTO & JTO CRR from ConcertAI, Flatiron Clinical-Genomics, and COTA databases 2018-22. Overall, median OS 28.6m and 5y OS 18%. Stark reminder that attrition is real: 33% received no 2L therapy.”

Title: Overall Survival in EGFR-mutant Advanced Non-Small Cell Lung Cancer Treated with First-line Osimertinib: A Cohort Study Integrating Clinical and Biomarker Data in the United States

Journal of Thoracic Oncology

Authors: Joshua K. Sabaria, Helena A. Yub, Parthiv J. Mahadeviac, Yanfang Liud, Levon Demirdjiane, Yen Hua Chend, Xiayi Wangf, Antonio Passaro

Read the Full Article.

Luis E. Raez

Luis E. Raez: Always use the best therapy first in EGFR NSCLC

“This is important data because its real world and give as a reason to always use the best therapy first, in the EGFR case is combination therapy either MARIPOSA or FLAURA2, no more single therapy unless there is a reason.”

“Real world outcomes for EGFR NSCLC with 1L osimertinib JTO & JTO CRR from ConcertAI, Flatiron Clinical-Genomics, and COTA databases 2018-22. Overall, median OS 28.6m and 5y OS 18%. Stark reminder that attrition is real: 33% received no 2L therapy.”